265 related articles for article (PubMed ID: 22447467)
21. Impact of angiotensin receptor blockade in combination with hydrochlorothiazide 25 mg in 2121 patients with stage 1-2 hypertension.
White WB; Davidai G; Schumacher H
J Hum Hypertens; 2009 Dec; 23(12):817-25. PubMed ID: 19357698
[TBL] [Abstract][Full Text] [Related]
22. Angiotensin II receptor antagonist telmisartan in isolated systolic hypertension (ARAMIS) study: efficacy and safety of telmisartan 20, 40 or 80 mg versus hydrochlorothiazide 12.5 mg or placebo.
Manolis AJ; Reid JL; de Zeeuw D; Murphy MB; Seewaldt-Becker E; Köster J;
J Hypertens; 2004 May; 22(5):1033-7. PubMed ID: 15097245
[TBL] [Abstract][Full Text] [Related]
23. Antihypertensive efficacy and tolerability of candesartan-hydrochlorothiazide 32/12.5 mg and 32/25 mg in patients not optimally controlled with candesartan monotherapy.
Bönner G;
Blood Press Suppl; 2008 Dec; 2():22-30. PubMed ID: 19203019
[TBL] [Abstract][Full Text] [Related]
24. Candesartan cilexetil 32 mg/hydrochlorothiazide 25 mg in unselected patients with high or very high cardiovascular risk: efficacy, safety, and metabolic impact.
Bramlage P; Buhck H; Zemmrich C
Clin Drug Investig; 2014 Apr; 34(4):241-9. PubMed ID: 24482018
[TBL] [Abstract][Full Text] [Related]
25. Combination therapy versus monotherapy as initial treatment for stage 2 hypertension: a prespecified subgroup analysis of a community-based, randomized, open-label trial.
Everett BM; Glynn RJ; Danielson E; Ridker PM;
Clin Ther; 2008 Apr; 30(4):661-72. PubMed ID: 18498915
[TBL] [Abstract][Full Text] [Related]
26. Candesartan cilexetil plus hydrochlorothiazide combination: a review of its use in hypertension.
Melian EB; Jarvis B
Drugs; 2002; 62(5):787-816. PubMed ID: 11929332
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety of two dosages of canrenone as add-on therapy in hypertensive patients taking ace-inhibitors or angiotensin II receptor blockers and hydrochlorothiazide at maximum dosage in a randomized clinical trial: The ESCAPE-IT trial.
Derosa G; Maffioli P; D'Avino M; Sala C; Mugellini A; Vulpis V; Felis S; Guasti L; Sarzani R; Bestetti A; Vanasia M; Gaudio G;
Cardiovasc Ther; 2017 Feb; 35(1):47-54. PubMed ID: 27860389
[TBL] [Abstract][Full Text] [Related]
28. Candesartan plus hydrochlorothiazide fixed combination vs previous monotherapy plus diuretic in poorly controlled essential hypertensive patients.
Mancia G; Omboni S;
Blood Press Suppl; 2004 Dec; 2():11-7. PubMed ID: 15631278
[TBL] [Abstract][Full Text] [Related]
29. A randomized titrate-to-target study comparing fixed-dose combinations of azilsartan medoxomil and chlorthalidone with olmesartan and hydrochlorothiazide in stage-2 systolic hypertension.
Cushman WC; Bakris GL; White WB; Weber MA; Sica D; Roberts A; Lloyd E; Kupfer S
J Hypertens; 2018 Apr; 36(4):947-956. PubMed ID: 29334491
[TBL] [Abstract][Full Text] [Related]
30. Comparison of fixed-dose combinations of telmisartan/hydrochlorothiazide 40/12.5 mg and 80/12.5 mg and a fixed-dose combination of losartan/hydrochlorothiazide 50/12.5 mg in mild to moderate essential hypertension: pooled analysis of two multicenter, prospective, randomized, open-label, blinded-end point (PROBE) trials.
Lacourcière Y; Neutel JM; Schumacher H
Clin Ther; 2005 Nov; 27(11):1795-805. PubMed ID: 16368450
[TBL] [Abstract][Full Text] [Related]
31. The role of baseline blood pressure in guiding treatment choice: a secondary analysis of the use of valsartan/hydrochlorothiazide as initial therapy in hypertensive adults in a randomized, double-blind, placebo-controlled trial.
Pool JL; Glazer R; Crikelair N; Levy D
Clin Drug Investig; 2009; 29(12):791-802. PubMed ID: 19888785
[TBL] [Abstract][Full Text] [Related]
32. Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study.
Ruilope LM; Malacco E; Khder Y; Kandra A; Bönner G; Heintz D
Clin Ther; 2005 May; 27(5):578-87. PubMed ID: 15978306
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of olmesartan/amlodipine/hydrochlorothiazide in patients with hypertension not at goal with mono, dual or triple drug therapy: results of the CHAMPiOn study.
Punzi HA
Ther Adv Cardiovasc Dis; 2014 Feb; 8(1):12-21. PubMed ID: 24492985
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of a stepped-care regimen using olmesartan medoxomil, amlodipine and hydrochlorothiazide in patients with moderate-to-severe hypertension: an open-label, long-term study.
Volpe M; Miele C; Haag U
Clin Drug Investig; 2009; 29(6):381-91. PubMed ID: 19432498
[TBL] [Abstract][Full Text] [Related]
35. Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study).
Lindholm LH; Persson M; Alaupovic P; Carlberg B; Svensson A; Samuelsson O
J Hypertens; 2003 Aug; 21(8):1563-74. PubMed ID: 12872052
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and tolerability of olmesartan medoxomil in patients with mild to moderate essential hypertension: the OLMEBEST Study.
Barrios V; Boccanelli A; Ewald S; Girerd X; Heagerty A; Krzesinski JM; Lins R; Rodicio J; Stefenelli T; Woittiez A; Böhm M
Clin Drug Investig; 2007; 27(8):545-58. PubMed ID: 17638395
[TBL] [Abstract][Full Text] [Related]
37. Hydrochlorothiazide, but not Candesartan, aggravates insulin resistance and causes visceral and hepatic fat accumulation: the mechanisms for the diabetes preventing effect of Candesartan (MEDICA) Study.
Eriksson JW; Jansson PA; Carlberg B; Hägg A; Kurland L; Svensson MK; Ahlström H; Ström C; Lönn L; Ojbrandt K; Johansson L; Lind L
Hypertension; 2008 Dec; 52(6):1030-7. PubMed ID: 18981327
[TBL] [Abstract][Full Text] [Related]
38. Combination therapy with olmesartan medoxomil and hydrochlorothiazide: secondary analysis of the proportion of patients achieving recommended blood pressure goals from a randomized, double-blind, factorial study.
Chrysant SG; Chavanu KJ; Xu J
Am J Cardiovasc Drugs; 2009; 9(4):241-51. PubMed ID: 19655819
[TBL] [Abstract][Full Text] [Related]
39. Olmesartan medoxomil in elderly patients with essential or isolated systolic hypertension : efficacy and safety data from clinical trials.
Heagerty AM; Mallion JM
Drugs Aging; 2009; 26(1):61-76. PubMed ID: 19102515
[TBL] [Abstract][Full Text] [Related]
40. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial.
Lithell H; Hansson L; Skoog I; Elmfeldt D; Hofman A; Olofsson B; Trenkwalder P; Zanchetti A;
J Hypertens; 2003 May; 21(5):875-86. PubMed ID: 12714861
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
